Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204)

(2021) Hussein A Tawbi et al.   NEURO-ONCOLOGY

Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

(2021) Anna Maria Di Giacomo et al.   CLINICAL CANCER RESEARCH

Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis.

(2021) Hussein Abdul-Hassan Tawbi et al.   JOURNAL OF CLINICAL ONCOLOGY

Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).

(2021) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

(2021) Evan J. Lipson et al.   JOURNAL OF CLINICAL ONCOLOGY

Melanoma brain metastases – Interdisciplinary management recommendations 2020

(2020) Ralf Gutzmer et al.   CANCER TREATMENT REVIEWS

Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy‐Mediated Systemic Control

(2019) Christopher Alvarez‐Breckenridge et al.   ONCOLOGIST

The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta‐analysis

(2019) Eliana Rulli et al.   CANCER

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

(2018) Georgina V Long et al.   LANCET ONCOLOGY

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

(2018) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial

(2018) Harriet M. Kluger et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

(2017) Michael A Davies et al.   LANCET ONCOLOGY

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study

(2017) Daniel N Cagney et al.   NEURO-ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response assessment criteria for brain metastases: proposal from the RANO group

(2015) Nancy U Lin et al.   LANCET ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

(2012) Kim Margolin et al.   LANCET ONCOLOGY

Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis

(2011) O. Amit et al.   EUROPEAN JOURNAL OF CANCER

Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases

(2011) Paul W. Sperduto et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic factors for survival in melanoma patients with brain metastases

(2010) Michael A. Davies et al.   CANCER

Lessons learned from independent central review

(2008) R. Ford et al.   EUROPEAN JOURNAL OF CANCER